Keyphrases
Left Ventricular Assist Device
62%
Heart Failure
51%
Acute Decompensated Heart Failure
42%
Acute Heart Failure
35%
Patients with Heart Failure
27%
Heart Failure with Preserved Ejection Fraction (HFpEF)
26%
Sacubitril-valsartan
26%
Left Ventricular Assist Device Implantation
25%
Bleeding
18%
Orthotopic Heart Transplantation
18%
Heart Transplant
16%
Risk Score
16%
Continuous-flow Left Ventricular Assist Device (CF-LVAD)
15%
Reduced Ejection Fraction
14%
Heart Failure Hospitalization
14%
Decongestion
13%
Driveline
12%
Heart Transplantation
12%
End-stage Heart Failure
11%
HeartMate
11%
Randomized Clinical Trial
11%
Optimization Strategy
11%
Non-associated
10%
Clinical Outcomes
10%
HeartMate II
10%
Heart Failure Trials
10%
Confidence Interval
10%
Weight Loss
10%
Adjusted Odds Ratio
9%
Treatment Strategy
9%
Hospitalization
9%
Strategy Evaluation
9%
HeartMate 3
9%
Angiotensin Receptor-neprilysin Inhibitor
9%
Diuretics
9%
Comorbidity
8%
Tolerability
8%
Readmission
8%
Congestion
8%
Cardiorenal
8%
Chronic Heart Failure
8%
Right Ventricular Function
8%
Left Ventricular Assist Device Support
7%
Causes of Readmission
7%
Heart Failure Care
7%
Left Ventricular Assist Device Therapy
6%
Right Ventricular
6%
Retrospective Cohort
6%
Furosemide
6%
Antibody-mediated Rejection
6%
Medicine and Dentistry
Left Ventricular Assist Device
100%
Congestive Heart Failure
73%
Acute Decompensated Heart Failure
34%
Heart Graft
27%
Infection
21%
Heart Transplantation
16%
Bleeding
15%
Odds Ratio
12%
Implant
11%
Heart Failure with Preserved Ejection Fraction
11%
Device Infection
11%
Assisted Circulation
10%
Diuretics
9%
Hazard Ratio
9%
Cardiovascular System
8%
Myocardial Disease
8%
Comorbidity
7%
Heart Right Ventricle Failure
7%
Apoplexy
7%
Quality of Life
7%
Diabetes
7%
Frailty
6%
Cohort Effect
6%
Messenger RNA
6%
Ejection Fraction
6%
Device Therapy
6%
Antibody Mediated Rejection
6%
Clinical Significance
6%
Biological Marker
6%
Outpatient
6%
Sodium Bicarbonate
6%
Systolic Blood Pressure
6%
Exercise
6%
Cardiotoxicity
6%
Sepsis
6%
Transplantation
5%
Angiotensin Receptor Antagonist
5%
Soft Tissue Sarcoma
5%
Tertiary Care
5%
Antibiotic Therapy
5%
COVID-19
5%
Fluorescence in Situ Hybridization
5%
Dexrazoxane
5%
Acute Myeloid Leukemia
5%
Whole Genome Sequencing
5%
Angiotensin II
5%
Anticoagulation
5%
Clinical Prediction Rule
5%
Renin Angiotensin Aldosterone System
5%
Acute Heart Infarction
5%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
85%
Acute Heart Failure
29%
Valsartan/Sacubitril
27%
Bleeding
13%
Comorbidity
12%
Heart Failure with Preserved Ejection Fraction
12%
Randomized Clinical Trial
11%
Myocardial Disease
9%
Enkephalinase Inhibitor
8%
Heart Failure with Reduced Ejection Fraction
8%
Cerebrovascular Accident
8%
Tolerability
8%
Frailty
6%
Dicarbonate
6%
Brain Hemorrhage
6%
Angiotensin
6%
Renin
6%
Biological Marker
5%
Brain Natriuretic Peptide
5%
Doxorubicin
5%
Soft Tissue Sarcoma
5%
Antidepressant
5%
Olaratumab
5%
Razoxane
5%
Thrombosis
5%
Bosentan
5%
Aldosterone
5%
Acute Heart Infarction
5%
Liraglutide
5%
Serum Albumin
5%
Pulmonary Hypertension
5%
Sepsis
5%
Membrane Metalloendopeptidase
5%
Messenger RNA
5%
Combination Therapy
5%